Eli Lilly reaches new highs! JPMorgan raises Eli Lilly's target price! (In-depth)

Eli Lilly (LLY) stock reached a new high on July 8, 2026, with the most direct catalyst beingJPMorgan, a leading Wall Street investment bank, significantly raised its price target after market close on July 7.

1. Core Catalyst: JPMorgan Raises Price Target

JPMorgan analyst Chris Schott raised Eli Lilly’s price target from$1,300 to $1,400, maintaining an “Overweight” rating. This target is notably above Wall Street’s average of $1,243, implying about a17% upside from the July 6 closing price.

The analyst’s report clearly stated the bull-case logic for Eli Lilly is:

• Continued ramp-up of Mounjaro internationally

• Robust growth in the US obesity market

• Projectedtotal sales this quarter to reach $20.7 billion (about $300 million above consensus),earnings per share (EPS) $8.85 (up $0.13)

2. Other Positive Signals from Wall Street Investment Banks

Prior to JPMorgan, other banks have already sent positive signals:

Cantor Fitzgerald specifically stated that major biopharmaceutical companies are expected to report strong overall Q2 2026 results and may guide for higher full-year revenues.

3. Strong Growth Forecast for the GLP-1 Product Line

Investment bank reports generally emphasize that Eli Lilly’s growth driver is itsGLP-1 weight-loss drug product line:

• Zepbound (obesity indication) maintaining strong demand in the US

• Mounjaro (diabetes indication) continued expansion internationally

• Oral drug orforglipron (Foundayo) andtriple-agonist retatrutide and other next-gen assets continue to raise market expectations

4. Additional Positive Factors in Recent Weeks

In recent weeks, Eli Lilly has accumulated several additional positives:

1. US Medicare GLP-1 Bridge Program: From July 1, 2026, eligible insured patients can access Zepbound and Foundayo with a copay of just $50/month, expected to greatly expand patient access

2. Cancer drug Jaypirca gains European support: The European Medicines Agency Committee for Medicinal Products for Human Use supports its use for chronic lymphocytic leukemia, paving the way for final EU approval

3. Sector rotation effect: On July 8, US equity markets saw funds rotate from chip stocks and other sectors to healthcare, with Eli Lilly as a leading pharma beneficiary

5. Fundamental Data Support

On a fundamental basis, Eli Lilly’s stock price has climbed about54%–58% over the past year, with a market cap reaching$1.1 trillion. Company revenue grew 47%, PEG ratio is only 0.33, and Piotroski Score reaches a perfect 9, reflecting robust financial health.

Summary: Eli Lilly’s record-high stock price is a result ofJPMorgan’s significant price target raise as a direct catalyst, combined withbroad bullishness from multiple investment banks,strong growth outlook for the GLP-1 pipeline, multiple recent positive developments andmarket sector rotation. The market will closely watchthe Q2 earnings to be released in August to validate analysts’ projections (sales of $20.7 billion, EPS of $8.85).